Alaunos Therapeutics raises $1.1M in direct sale
Alaunos Therapeutics, Inc. (TCRT) entered into definitive agreements for a registered direct offering of 380,469 shares of common stock and 386,654 Pre-Funded Warrants to purchase common stock.
Rhea-AI Filing Summary
Alaunos Therapeutics, Inc. (TCRT) entered into definitive agreements for a registered direct offering of 380,469 shares of common stock and 386,654 Pre-Funded Warrants to purchase common stock. The shares are priced at $1.46 each and the Pre-Funded Warrants at $1.459 each under an effective Form S-3 shelf registration.
The transaction closed on September 21, 2026 and generated approximately $1,120,000 in gross proceeds and about $915,400.50 in net proceeds after fees and expenses. Alaunos plans to use the net proceeds for general corporate purposes, including working capital. The Pre-Funded Warrants are exercisable immediately at $0.001 per share, have no expiration, and include a beneficial ownership limitation of 4.99% (or 9.99% if elected, with 60 days’ notice). Dawson James Securities, Inc. acted as exclusive placement agent and received an 8% cash fee on gross proceeds, and company officers and directors agreed to a 15-day lock-up on additional equity sales, subject to exceptions.
Positive
- None.
Negative
- None.
Filing Explained
The pre-funded warrants may be exercised for cash, but if no effective registration statement or current prospectus covers the underlying shares, they may instead be exercised cashlessly.
8-K Event Classification
3 items: 1.01, 8.01, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Common shares offered: 380,469 shares
Pre-Funded Warrants offered: 386,654 warrants
Offering price per share: $1.46 per share
+5 more
8 metrics
Common shares offered
380,469 shares
Shares of common stock sold in the registered direct offering
Pre-Funded Warrants offered
386,654 warrants
Pre-Funded Warrants to purchase common stock sold in the offering
Offering price per share
$1.46 per share
Purchase price for each share of common stock in the offering
Offering price per Pre-Funded Warrant
$1.459 per warrant
Purchase price for each Pre-Funded Warrant
Gross proceeds
$1,120,000
Aggregate gross proceeds from the offering before fees and expenses
Net proceeds
$915,400.50
Net proceeds to Alaunos after estimated offering expenses
Warrant exercise price
$0.001 per share
Exercise price of the Pre-Funded Warrants for underlying common stock
Beneficial ownership limitation
4.99% or 9.99%
Cap on holder’s beneficial ownership of outstanding common stock
Key Terms
registered direct offering, Pre-Funded Warrants, beneficial ownership limitation, lock-up agreement, +1 more
5 terms
registered direct offering financial
"entered into a securities purchase agreement ... in a registered direct offering"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
Pre-Funded Warrants financial
"386,654 pre-funded warrants (the “Pre-Funded Warrants”) to purchase shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
beneficial ownership limitation financial
"The exercise of the Pre-Funded Warrants will be subject to a beneficial ownership limitation"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
lock-up agreement financial
"each of the Company’s officers and directors entered into a lock-up agreement"
A lock-up agreement is a contract that prevents company insiders and early investors from selling their shares for a fixed period after a stock sale, often after an initial public offering. It matters to investors because it temporarily limits the number of shares that can hit the market, which can keep the share price steadier; when the lock-up ends, a sudden increase in available shares can create extra volatility, revealing insiders’ confidence or lack thereof.
at-the-market under Nasdaq rules financial
"Registered Direct Offering priced at-the-market under Nasdaq rules"
Offering Details
shelf
Offering
Offering Type
shelf
Use of Proceeds
General corporate purposes, including working capital
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Alaunos Therapeutics (TCRT) announce in this 8-K?
Alaunos Therapeutics announced a registered direct offering of 380,469 shares of common stock and 386,654 Pre-Funded Warrants, priced at $1.46 per share (and $1.459 per Pre-Funded Warrant), conducted under its effective Form S-3 shelf registration statement.
How much capital did TCRT raise in this registered direct offering?
The offering generated approximately $1,120,000 in gross proceeds and about $915,400.50 in net proceeds after estimated offering expenses, including placement agent fees, to Alaunos Therapeutics.
What are the key terms of Alaunos Therapeutics’ Pre-Funded Warrants?
The Pre-Funded Warrants cover 386,654 shares, are exercisable starting on the issuance date at an exercise price of $0.001 per share, have no expiration, and may be exercised for cash or on a cashless basis if no effective registration is available for the underlying common stock.
What is the beneficial ownership limitation on TCRT’s Pre-Funded Warrants?
The Pre-Funded Warrants include a beneficial ownership limitation that generally caps ownership at 4.99% of outstanding common stock, or 9.99% if elected by a purchaser. The cap can be adjusted up or down (up to 9.99%) with 60 days’ advance notice.
How will Alaunos Therapeutics use the proceeds from this offering?
Alaunos Therapeutics intends to use the net proceeds of about $915,400.50 primarily for general corporate purposes, including working capital, as disclosed in the filing and related offering documents.
What lock-up arrangements apply to Alaunos Therapeutics’ insiders after this offering?
Each officer and director entered into a 15-day lock-up agreement starting from the date of the offering, restricting the offer, sale, transfer, or registration of company equity securities, subject to specified exceptions.
Who acted as placement agent for the Alaunos Therapeutics (TCRT) offering and what was the fee?
Dawson James Securities, Inc. acted as the exclusive placement agent. Alaunos paid a cash fee of 8% of aggregate gross proceeds from the offering and reimbursed certain expenses of the placement agent.
AI-generated analysis. How Rhea-AI works. Not financial advice.
